Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Pipeline Analysis

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1722140

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1722140

Primary Hepatocytes Market - Global Primary Hepatocytes Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025-2032 - (By Product, By Species, By Application/Assay, By End User, By Geographic Coverage and By Company)

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 8495
Printable PDF & Excel (Enterprise License above 5 users)
USD 10600

Add to Cart

Description

Table of Contents

The global primary hepatocytes market is poised for substantial growth over the coming years, reaching an estimated valuation of US$ 406.9 million by 2032. This marks a significant increase from the US$ 263.6 million recorded in 2025, reflecting a compound annual growth rate (CAGR) of 6.4% during the forecast period from 2025 to 2032. The surge is largely attributed to the escalating prevalence of liver-related diseases and the increasing demand for more predictive in vitro models in drug development and toxicology testing.

Market Insights

Primary hepatocytes have become a cornerstone in liver disease research, preclinical drug testing, and toxicological assessments. Their ability to accurately mimic liver function makes them ideal for investigating drug metabolism, enzyme activity, and hepatotoxicity. Recent advancements in 3D culture systems, such as spheroids and co-culture technologies, are elevating the relevance of hepatocyte-based assays by enabling closer simulation of the in vivo liver microenvironment.

Researchers and pharmaceutical companies are increasingly turning to stem cell-derived hepatocytes to overcome supply limitations while maintaining functional integrity. This trend, coupled with a growing focus on ethical research practices and regulatory pressure to reduce animal testing, is driving the widespread adoption of hepatocyte-based in vitro systems.

Market Drivers

One of the key drivers of the market is the increasing incidence of liver diseases, including Non-Alcoholic Fatty Liver Disease (NAFLD) and hepatitis. These conditions are generating demand for reliable in vitro models that can effectively support drug discovery and therapeutic testing. Primary hepatocytes, which offer a close representation of human liver cells, are essential tools in this regard.

Another major factor fueling market growth is the global rise in cancer prevalence. The World Health Organization (WHO) anticipates a 47% increase in cancer cases by 2040, which underscores the urgent need for more effective drug screening methods. 3D hepatocyte models are proving invaluable in oncology research, offering greater predictive power in assessing drug toxicity and efficacy. Leading companies such as Lonza and Thermo Fisher Scientific are actively investing in organ-on-a-chip and 3D liver models to meet this demand.

Additionally, regulatory bodies like the FDA and EMA are emphasizing the use of human-relevant in vitro models to improve early-stage drug screening and reduce animal testing. This regulatory support is further solidifying the role of primary hepatocytes in modern drug development.

Business Opportunities

The market is brimming with opportunities, especially in the wake of growing interest in 3D cell culture technologies. These systems replicate complex tissue architecture, offering more accurate insights into biological processes such as tumor growth, metastasis, and drug resistance. Organoids created from patient-derived cells are paving the way for personalized medicine applications.

Moreover, stricter animal testing regulations are opening new avenues for hepatocyte-based models. Companies are capitalizing on this shift by developing innovative screening tools that align with evolving ethical standards while enhancing the reliability of preclinical studies. The demand for scalable, cost-effective solutions also presents opportunities for startups and emerging players to innovate and expand.

Regional Analysis

North America remains the dominant region in the global primary hepatocytes market. Its advanced healthcare infrastructure, substantial investment in R&D, and strong presence of pharmaceutical and biotechnology companies contribute to its leading position. The high incidence of liver disorders and a regulatory environment that supports innovative drug development practices are also driving demand.

Europe is another key region experiencing robust growth, fueled by its well-established pharmaceutical sector and progressive regulatory policies. Countries like Germany, France, and the United Kingdom are leading efforts in integrating in vitro systems into drug development pipelines. The European Medicines Agency (EMA) continues to promote alternatives to animal testing, thereby supporting increased adoption of primary hepatocytes.

Key Players

The competitive landscape is characterized by strategic investments, product innovations, and collaborations among major industry players. Companies are focusing on improving cell isolation techniques, cryopreservation technologies, and assay compatibility to meet the evolving demands of the market.

Prominent players in the primary hepatocytes market include:

  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Lonza
  • Takara Bio Inc.
  • American Type Culture Collection (ATCC)
  • Corning Inc.
  • Cell Biologics, Inc.
  • Creative Bioarray
  • Axol Bioscience Ltd.
  • HiMedia Laboratories
  • AnaBios
  • Cytes Biotechnologies S.L.
  • ZenBio, Inc. (BioIVT)
  • iXCells Biotechnologies
  • ScienCell Research Laboratories, Inc.
  • Kerafast
  • Kosheeka
  • XenoTech
  • LifeNet Health LifeSciences
  • Applied Biological Materials Inc. (abm)
  • Discovery Life Sciences
  • Innoprot
  • Novabiosis

Recent Industry Developments

In March 2024, Merck invested US$ 14 million in its M Lab(TM) Collaboration Center in Shanghai, expanding its offerings with new biological application and training labs to support biopharma research.

In February 2024, Merck opened a US$ 20 million distribution center in Sao Paulo, Brazil, aimed at improving service efficiency for its life science clients in Latin America.

In February 2023, ATCC entered a long-term partnership with the U.S. Pharmacopeia (USP) to co-develop reference materials and standards for biologic medicines, bolstering quality and compliance.

Market Segmentation

By Product:

  • Cryopreserved Suspension Hepatocytes
  • Fresh Suspension Hepatocytes
  • 3D (Spheroid) Hepatocytes
  • Expanded Hepatocytes (Plateable)
  • Non-characterized Hepatocytes

By Species:

  • Human
  • Rat
  • Mouse
  • Dog
  • Monkey
  • Horse
  • Others

By Application/Assay:

  • Cell Viability Assay
  • Cytochrome Enzyme Activity
  • High Content Cytotoxicity
  • Transporter Inhibition Assay
  • In Vitro Intrinsic Clearance
  • Phospholipids Assay
  • Others

By End User:

  • Biopharmaceutical Companies
  • Academic and Research Institutes
  • Contract Research Organizations

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Primary Hepatocytes Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2025
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Economic Overview
    • 2.6.1. World Economic Projections
  • 2.7. PESTLE Analysis
  • 2.8. Primary Hepatocytes Market, Product Adoption
  • 2.9. Regulatory Scenario by Region
  • 2.10. Value Chain Analysis

3. Global Primary Hepatocytes Market Outlook, 2019-2032

  • 3.1. Global Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 3.1.1. Key Highlights
      • 3.1.1.1. Cryopreserved Suspension Hepatocytes
      • 3.1.1.2. Fresh Suspension Hepatocytes
      • 3.1.1.3. 3D (Spheroid) Hepatocytes
      • 3.1.1.4. Expanded Hepatocytes (Plateable)
      • 3.1.1.5. Non-characterized Hepatocytes
  • 3.2. Global Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 3.2.1. Key Highlights
      • 3.2.1.1. Human
      • 3.2.1.2. Rat
      • 3.2.1.3. Mouse
      • 3.2.1.4. Dog
      • 3.2.1.5. Monkey
      • 3.2.1.6. Horse
      • 3.2.1.7. Others
  • 3.3. Global Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 3.3.1. Key Highlights
      • 3.3.1.1. Cell Viability Assay
      • 3.3.1.2. Cytochrome Enzyme Activity
      • 3.3.1.3. High Content Cytotoxicity
      • 3.3.1.4. Transporter Inhibition Assay
      • 3.3.1.5. In Vitro Intrinsic Clearance
      • 3.3.1.6. Phospholipids Assay
      • 3.3.1.7. Others
  • 3.4. Global Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 3.4.1. Key Highlights
      • 3.4.1.1. Biopharmaceutical companies
      • 3.4.1.2. Academic and Research institutes
      • 3.4.1.3. Contract Research Organizations
  • 3.5. Global Primary Hepatocytes Market Outlook, by Region, Value (US$ Mn), 2019-2032
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. East Asia
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Primary Hepatocytes Market Outlook, 2019-2032

  • 4.1. North America Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 4.1.1. Key Highlights
      • 4.1.1.1. Cryopreserved Suspension Hepatocytes
      • 4.1.1.2. Fresh Suspension Hepatocytes
      • 4.1.1.3. 3D (Spheroid) Hepatocytes
      • 4.1.1.4. Expanded Hepatocytes (Plateable)
      • 4.1.1.5. Non-characterized Hepatocytes
  • 4.2. North America Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 4.2.1. Key Highlights
      • 4.2.1.1. Human
      • 4.2.1.2. Rat
      • 4.2.1.3. Mouse
      • 4.2.1.4. Dog
      • 4.2.1.5. Monkey
      • 4.2.1.6. Horse
      • 4.2.1.7. Others
  • 4.3. North America Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 4.3.1. Key Highlights
      • 4.3.1.1. Cell Viability Assay
      • 4.3.1.2. Cytochrome Enzyme Activity
      • 4.3.1.3. High Content Cytotoxicity
      • 4.3.1.4. Transporter Inhibition Assay
      • 4.3.1.5. In Vitro Intrinsic Clearance
      • 4.3.1.6. Phospholipids Assay
      • 4.3.1.7. Others
  • 4.4. North America Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 4.4.1. Key Highlights
      • 4.4.1.1. Biopharmaceutical companies
      • 4.4.1.2. Academic and Research institutes
      • 4.4.1.3. Contract Research Organizations
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis
  • 4.5. North America Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 4.5.1.2. U.S. Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 4.5.1.3. U.S. Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 4.5.1.4. U.S. Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 4.5.1.5. Canada Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 4.5.1.6. Canada Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 4.5.1.7. Canada Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 4.5.1.8. Canada Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Primary Hepatocytes Market Outlook, 2019-2032

  • 5.1. Europe Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Cryopreserved Suspension Hepatocytes
      • 5.1.1.2. Fresh Suspension Hepatocytes
      • 5.1.1.3. 3D (Spheroid) Hepatocytes
      • 5.1.1.4. Expanded Hepatocytes (Plateable)
      • 5.1.1.5. Non-characterized Hepatocytes
  • 5.2. Europe Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Human
      • 5.2.1.2. Rat
      • 5.2.1.3. Mouse
      • 5.2.1.4. Dog
      • 5.2.1.5. Monkey
      • 5.2.1.6. Horse
      • 5.2.1.7. Others
  • 5.3. Europe Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Cell Viability Assay
      • 5.3.1.2. Cytochrome Enzyme Activity
      • 5.3.1.3. High Content Cytotoxicity
      • 5.3.1.4. Transporter Inhibition Assay
      • 5.3.1.5. In Vitro Intrinsic Clearance
      • 5.3.1.6. Phospholipids Assay
      • 5.3.1.7. Others
  • 5.4. Europe Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 5.4.1. Key Highlights
      • 5.4.1.1. Biopharmaceutical companies
      • 5.4.1.2. Academic and Research institutes
      • 5.4.1.3. Contract Research Organizations
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis
  • 5.5. Europe Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.2. Germany Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.3. Germany Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.4. Germany Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.5. U.K. Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.6. U.K. Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.7. U.K. Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.8. U.K. Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.9. France Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.10. France Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.11. France Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.12. France Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.13. Spain Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.14. Spain Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.15. Spain Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.16. Spain Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.17. Italy Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.18. Italy Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.19. Italy Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.20. Italy Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.21. Russia Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.22. Russia Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.23. Russia Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.24. Russia Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.25. Rest of Europe Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.26. Rest of Europe Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.27. Rest of Europe Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.28. Rest of Europe Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia & Pacific Primary Hepatocytes Market Outlook, 2019-2032

  • 6.1. Asia Pacific Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Cryopreserved Suspension Hepatocytes
      • 6.1.1.2. Fresh Suspension Hepatocytes
      • 6.1.1.3. 3D (Spheroid) Hepatocytes
      • 6.1.1.4. Expanded Hepatocytes (Plateable)
      • 6.1.1.5. Non-characterized Hepatocytes
  • 6.2. Asia Pacific Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Human
      • 6.2.1.2. Rat
      • 6.2.1.3. Mouse
      • 6.2.1.4. Dog
      • 6.2.1.5. Monkey
      • 6.2.1.6. Horse
      • 6.2.1.7. Others
  • 6.3. Asia Pacific Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. Cell Viability Assay
      • 6.3.1.2. Cytochrome Enzyme Activity
      • 6.3.1.3. High Content Cytotoxicity
      • 6.3.1.4. Transporter Inhibition Assay
      • 6.3.1.5. In Vitro Intrinsic Clearance
      • 6.3.1.6. Phospholipids Assay
      • 6.3.1.7. Others
  • 6.4. Asia Pacific Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 6.4.1. Key Highlights
      • 6.4.1.1. Biopharmaceutical companies
      • 6.4.1.2. Academic and Research institutes
      • 6.4.1.3. Contract Research Organizations
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. Asia & Pacific Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.2. China Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.3. China Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.4. China Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.5. Japan Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.6. Japan Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.7. Japan Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.8. Japan Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.9. South Korea Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.10. South Korea Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.11. South Korea Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.12. South Korea Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.13. India Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.14. India Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.15. India Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.16. India Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.17. Southeast Asia Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.18. Southeast Asia Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.19. Southeast Asia Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.20. Southeast Asia Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.21. Rest of Asia Pacific Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.22. Rest of Asia Pacific Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.23. Rest of Asia Pacific Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.24. Rest of Asia Pacific Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Primary Hepatocytes Market Outlook, 2019-2032

  • 7.1. Latin America Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Cryopreserved Suspension Hepatocytes
      • 7.1.1.2. Fresh Suspension Hepatocytes
      • 7.1.1.3. 3D (Spheroid) Hepatocytes
      • 7.1.1.4. Expanded Hepatocytes (Plateable)
      • 7.1.1.5. Non-characterized Hepatocytes
  • 7.2. Latin America Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Human
      • 7.2.1.2. Rat
      • 7.2.1.3. Mouse
      • 7.2.1.4. Dog
      • 7.2.1.5. Monkey
      • 7.2.1.6. Horse
      • 7.2.1.7. Others
  • 7.3. Latin America Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Cell Viability Assay
      • 7.3.1.2. Cytochrome Enzyme Activity
      • 7.3.1.3. High Content Cytotoxicity
      • 7.3.1.4. Transporter Inhibition Assay
      • 7.3.1.5. In Vitro Intrinsic Clearance
      • 7.3.1.6. Phospholipids Assay
      • 7.3.1.7. Others
  • 7.4. Latin America Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 7.4.1. Key Highlights
      • 7.4.1.1. Biopharmaceutical companies
      • 7.4.1.2. Academic and Research institutes
      • 7.4.1.3. Contract Research Organizations
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Latin America Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 7.5.1.2. Brazil Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 7.5.1.3. Brazil Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 7.5.1.4. Brazil Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 7.5.1.5. Mexico Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 7.5.1.6. Mexico Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 7.5.1.7. Mexico Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 7.5.1.8. Mexico Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 7.5.1.9. Rest of Latin America Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 7.5.1.10. Rest of Latin America Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 7.5.1.11. Rest of Latin America Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 7.5.1.12. Rest of Latin America Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Primary Hepatocytes Market Outlook, 2019-2032

  • 8.1. Middle East & Africa Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Cryopreserved Suspension Hepatocytes
      • 8.1.1.2. Fresh Suspension Hepatocytes
      • 8.1.1.3. 3D (Spheroid) Hepatocytes
      • 8.1.1.4. Expanded Hepatocytes (Plateable)
      • 8.1.1.5. Non-characterized Hepatocytes
  • 8.2. Middle East & Africa Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 8.2.1. Key Highlights
      • 8.2.1.1. Human
      • 8.2.1.2. Rat
      • 8.2.1.3. Mouse
      • 8.2.1.4. Dog
      • 8.2.1.5. Monkey
      • 8.2.1.6. Horse
      • 8.2.1.7. Others
  • 8.3. Middle East & Africa Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. Cell Viability Assay
      • 8.3.1.2. Cytochrome Enzyme Activity
      • 8.3.1.3. High Content Cytotoxicity
      • 8.3.1.4. Transporter Inhibition Assay
      • 8.3.1.5. In Vitro Intrinsic Clearance
      • 8.3.1.6. Phospholipids Assay
      • 8.3.1.7. Others
  • 8.4. Middle East & Africa Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 8.4.1. Key Highlights
      • 8.4.1.1. Biopharmaceutical companies
      • 8.4.1.2. Academic and Research institutes
      • 8.4.1.3. Contract Research Organizations
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Middle East & Africa Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Countries Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.2. GCC Countries Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.3. GCC Countries Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 8.5.1.4. GCC Countries Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 8.5.1.5. South Africa Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.6. South Africa Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.7. South Africa Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 8.5.1.8. GCC Countries Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 8.5.1.9. Nigeria Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.10. Nigeria Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.11. Nigeria Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 8.5.1.12. Nigeria Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 8.5.1.13. Nigeria Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.14. Nigeria Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.15. Nigeria Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 8.5.1.16. Nigeria Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 8.5.1.17. Rest of Middle East & Africa Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.18. Rest of Middle East & Africa Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.19. Rest of Middle East & Africa Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Market Share Analysis, 2025
  • 9.2. Competitive Dashboard
  • 9.3. Company Profiles
    • 9.3.1. Thermo Fisher Scientific Inc.
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Product Portfolio
      • 9.3.1.3. Financial Overview
      • 9.3.1.4. Business Strategies and Development
    • 9.3.2. Merck KGaA
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Product Portfolio
      • 9.3.2.3. Financial Overview
      • 9.3.2.4. Business Strategies and Development
    • 9.3.3. Lonza
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Product Portfolio
      • 9.3.3.3. Financial Overview
      • 9.3.3.4. Business Strategies and Development
    • 9.3.4. Takara Bio Inc.
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Product Portfolio
      • 9.3.4.3. Financial Overview
      • 9.3.4.4. Business Strategies and Development
    • 9.3.5. American Type Culture Collection (ATCC)
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Product Portfolio
      • 9.3.5.3. Financial Overview
      • 9.3.5.4. Business Strategies and Development
    • 9.3.6. Corning Inc.
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Product Portfolio
      • 9.3.6.3. Financial Overview
      • 9.3.6.4. Business Strategies and Development
    • 9.3.7. Cell Biologics, Inc.
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Product Portfolio
      • 9.3.7.3. Financial Overview
      • 9.3.7.4. Business Strategies and Development
    • 9.3.8. Creative Bioarray
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Product Portfolio
      • 9.3.8.3. Financial Overview
      • 9.3.8.4. Business Strategies and Development
    • 9.3.9. Axol Bioscience Ltd.
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Product Portfolio
      • 9.3.9.3. Financial Overview
      • 9.3.9.4. Business Strategies and Development
    • 9.3.10. HiMedia Laboratories
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Product Portfolio
      • 9.3.10.3. Financial Overview
      • 9.3.10.4. Business Strategies and Development
    • 9.3.11. NEXEL Co., Ltd.
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Product Portfolio
      • 9.3.11.3. Financial Overview
      • 9.3.11.4. Business Strategies and Development
    • 9.3.12. AnaBios
      • 9.3.12.1. Company Overview
      • 9.3.12.2. Product Portfolio
      • 9.3.12.3. Financial Overview
      • 9.3.12.4. Business Strategies and Development
    • 9.3.13. Cytes Biotechnologies S.L.
      • 9.3.13.1. Company Overview
      • 9.3.13.2. Product Portfolio
      • 9.3.13.3. Financial Overview
      • 9.3.13.4. Business Strategies and Development
    • 9.3.14. ZenBio, Inc. (BioIVT)
      • 9.3.14.1. Company Overview
      • 9.3.14.2. Product Portfolio
      • 9.3.14.3. Financial Overview
      • 9.3.14.4. Business Strategies and Development
    • 9.3.15. iXCells Biotechnologies
      • 9.3.15.1. Company Overview
      • 9.3.15.2. Product Portfolio
      • 9.3.15.3. Financial Overview
      • 9.3.15.4. Business Strategies and Development
    • 9.3.16. ScienCell Research Laboratories, Inc.
      • 9.3.16.1. Company Overview
      • 9.3.16.2. Product Portfolio
      • 9.3.16.3. Financial Overview
      • 9.3.16.4. Business Strategies and Development
    • 9.3.17. Kerafast
      • 9.3.17.1. Company Overview
      • 9.3.17.2. Product Portfolio
      • 9.3.17.3. Financial Overview
      • 9.3.17.4. Business Strategies and Development
    • 9.3.18. Kosheeka
      • 9.3.18.1. Company Overview
      • 9.3.18.2. Product Portfolio
      • 9.3.18.3. Financial Overview
      • 9.3.18.4. Business Strategies and Development
    • 9.3.19. XenoTech
      • 9.3.19.1. Company Overview
      • 9.3.19.2. Product Portfolio
      • 9.3.19.3. Financial Overview
      • 9.3.19.4. Business Strategies and Development
    • 9.3.20. LifeNet Health LifeSciences
      • 9.3.20.1. Company Overview
      • 9.3.20.2. Product Portfolio
      • 9.3.20.3. Financial Overview
      • 9.3.20.4. Business Strategies and Development
    • 9.3.21. Cell Guidance Systems LLC
      • 9.3.21.1. Company Overview
      • 9.3.21.2. Product Portfolio
      • 9.3.21.3. Financial Overview
      • 9.3.21.4. Business Strategies and Development
    • 9.3.22. Applied Biological Materials Inc. (abm)
      • 9.3.22.1. Company Overview
      • 9.3.22.2. Product Portfolio
      • 9.3.22.3. Financial Overview
      • 9.3.22.4. Business Strategies and Development
    • 9.3.23. Discovery Life Sciences
      • 9.3.23.1. Company Overview
      • 9.3.23.2. Product Portfolio
      • 9.3.23.3. Financial Overview
      • 9.3.23.4. Business Strategies and Development
    • 9.3.24. Innoprot
      • 9.3.24.1. Company Overview
      • 9.3.24.2. Product Portfolio
      • 9.3.24.3. Financial Overview
      • 9.3.24.4. Business Strategies and Development
    • 9.3.25. Novabiosis
      • 9.3.25.1. Company Overview
      • 9.3.25.2. Product Portfolio
      • 9.3.25.3. Financial Overview
      • 9.3.25.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!